TY - JOUR
T1 - The clinical significance of human leukocyte antigen antibody development in kidney transplantation
AU - Lee, P. C.
AU - Chen, Y. L.
AU - Chou, T. C.
AU - Wang, W. M.
AU - Wang, J. D.
AU - Hung, C. J.
AU - Chang, S. S.
AU - Lin, Y. J.
AU - Chan, R. H.
PY - 2012/1
Y1 - 2012/1
N2 - Background: This retrospective study uses the LAT-M (One Lambda Inc., Calif) screen assay to reexamine the impacts (a), of pretransplant human leukocyte antigen (HLA) antibody on long-term graft survival; (b) posttransplant HLA antibody on long-term graft survival and (c) immunosuppressive regimen on posttransplant HLA antibody development. Patients and methods: Pretransplant sera from 222 renal transplant recipients and posttransplant sera from 216 renal transplant recipients were studied for the impact of HLA antibody on long-term graft survival. Results: Among the patients who did not display pretransplant HLA antibodies, 85% enjoyed 5-year and 59% 10-year graft survival, whereas the patients who tested positive were 83% and 83% (P =.5596). Among the patients who did not show posttransplant HLA antibodies, 99% enjoyed 5-, 91% 10-, and 65% 15-year graft survival, whereas for the 44 patients who tested positive they were 59%, 44%, and 30%, respectively (P <.0001). Patients prescribed cyclosporine + myfortic (odds ratio 0.17, P =.05) or FK + Cellcept (odds ratio 0.36, P =.04) showed the lowest posttransplant HLA antibody development. Conclusion: Both regimens improve graft survival.
AB - Background: This retrospective study uses the LAT-M (One Lambda Inc., Calif) screen assay to reexamine the impacts (a), of pretransplant human leukocyte antigen (HLA) antibody on long-term graft survival; (b) posttransplant HLA antibody on long-term graft survival and (c) immunosuppressive regimen on posttransplant HLA antibody development. Patients and methods: Pretransplant sera from 222 renal transplant recipients and posttransplant sera from 216 renal transplant recipients were studied for the impact of HLA antibody on long-term graft survival. Results: Among the patients who did not display pretransplant HLA antibodies, 85% enjoyed 5-year and 59% 10-year graft survival, whereas the patients who tested positive were 83% and 83% (P =.5596). Among the patients who did not show posttransplant HLA antibodies, 99% enjoyed 5-, 91% 10-, and 65% 15-year graft survival, whereas for the 44 patients who tested positive they were 59%, 44%, and 30%, respectively (P <.0001). Patients prescribed cyclosporine + myfortic (odds ratio 0.17, P =.05) or FK + Cellcept (odds ratio 0.36, P =.04) showed the lowest posttransplant HLA antibody development. Conclusion: Both regimens improve graft survival.
UR - http://www.scopus.com/inward/record.url?scp=84863355769&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863355769&partnerID=8YFLogxK
U2 - 10.1016/j.transproceed.2011.11.037
DO - 10.1016/j.transproceed.2011.11.037
M3 - Article
C2 - 22310628
AN - SCOPUS:84863355769
SN - 0041-1345
VL - 44
SP - 264
EP - 266
JO - Transplantation Proceedings
JF - Transplantation Proceedings
IS - 1
ER -